QUEBEC CITY--(BUSINESS WIRE)--Saguaro Technologies Inc. announces the closing of a $1.1M start-up financing led by a seasoned biotech investor and including non-dilutive grant funding.
“We are pleased to close our first financing and to welcome Frederic Ors as lead investor and strategic advisor to Saguaro. Frederic is a well-recognized executive with a track-record of successfully growing biotech companies,” said Louis Turcotte Co-Founder & Chief Executive Officer. “Frederic shares our vision on the potential of next-generation technologies to make drug discovery more successful and we are looking forward to benefit from his experience and network.”
“Capital from this round will be used for the full-scale rollout of Saguaro’s technologies allowing us to further sustain our rapid growth,” continued Félix Lavoie-Pérusse, Co-Founder & Chief Commercial Officer.
“I’m proud to join inspiring entrepreneurs like Louis and Felix in their quest to improve the drug discovery process for human health. They began this journey in 2020 and in an impressive short period of time, they have acquired key technologies and attracted large pharma and biotech companies as clients. I fondly anticipate to continue to work with them to accelerate and propel Saguaro to become an industry leader.”
About Saguaro
Saguaro is aspiring to become a leader in next-generation technologies that make drug discovery more successful. Our unique products help drug developers make the most of their in vitro models, with the goal of generating new data that is more predictive of results in clinical trials with humans.
Visit Saguaro’s website to learn more about their innovative cell culture products: https://www.saguarobio.com/
